It is associated with treatment-induced resistance to radiotherapy and tamoxifen [28], increased progression of ER-positive AI-resistant breast cancer cells [29], poorer prognosis in ER-positive luminal B breast cancer [59], and we saw here that IFN-expression was associated with poorer survival in the SCAN-B cohort. This evidence concerns the gene ESR1 and breast carcinoma.